

NEWSLETTER

VOLUME 1 ISSUE

09TH JULY 2007

Aim of the Register

To investigate the long-term outcome of patients with psoriasis treated with biologics and compare it to those patients treated with conventional systemic treatments (ciclosporin, methotrexate, acitretin and PUVA).





Recommendation from NICE and BAD that all patients treated with biological therapy should be registered with BADBIR

Study Design

COMPARE

Cohort 1

Patients with psoriasis newly exposed to biologic therapy

Including infliximat etanercept and efalizumah

Cohort 2

Patients with similar disease characteristics exposed to conventional therapy

Including PUVA, MTX, ciclosporin and acitretir

Primary Endpoints

- Any malignancy
- Any infection requiring hospitalisation
- Serious adverse events
- Death

Sample size

Accounting for losses to follow and deaths:

- Biologics n = 4000 (each one)
- Controls n = 4000
 (Recruited over 5 years)

Data Collection

Consultant: Web based transfer Patient: Paper questionnaires

Website: www.badbir.org/

BADBIR Office base:

arc Epidemiology Unit The University of Manchester Oxford Road Manchester

Study Co-ordinator: Kathy McElhone Phone: 0161 603 7731 E-mail:kathleen.mcelhone@manchester.ac.uk

Biological Cohort Eligibility Criteria

- Diagnosis of psoriasis
- Newly commencing on etanercept, infliximab or efalizumab
- Informed consent
- Aged 16+ yrs

Comparison Cohort Eligibility Criteria

- Diagnosis of psoriasis
- <u>Starting</u> or <u>switching</u> conventional therapy
- Informed consent
- Aged 16+ yrs

Baseline Data

Consultant

- Diagnosis and disease characteristics
- PASI
- DLQI
- EuroQoL
- Previous and current therapy

^**********

Patient

- Demographics
- Occupational Status

Consultant questionnaire Patient questionnaire & diary Office for National Statistics (ONS) flagging Year 0 Year 3 Year 5

Follow-up data

Consultant

- Changes in therapy
- Adverse event information including pathology/ microbiology reports
- Current PASI

Patient

- DLQI
- EuroQoL
- 6 monthly diary to record hospitalisations, new drugs and referrals

Pilot Study

BADBIR received MREC approval in March 2007. The pilot study will commence during August/September 2007. Seven initial centres have been approached to take part in the pilot study. The aims of the pilot are to:

- Test the proposed data collection tools
- Test and streamline the online data collection process
- Assess easiest methods for obtaining LREC/R&D approval for local recruiting centres



Funding

To help towards time spent collecting this data the following payment plan is available:

• Fully completed baseline form: £100

Fully completed follow-up form: £50

(total of 8 follow-up forms over five years)

Each centre will need to inform BADBIR which account to pay this to

